Telacebec for Ultrashort Treatment of Buruli Ulcer in a Mouse Model

Telacebec (Q203) is a new antitubercular drug with extremely potent activity against Mycobacterium ulcerans. Here, we explored the treatment-shortening potential of Q203 alone or in combination with rifampin (RIF) in a mouse footpad infection model. The first study compared Q203 at 5 and 10 mg/kg do...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Antimicrob Agents Chemother
Huvudupphovsmän: Almeida, Deepak V., Converse, Paul J., Omansen, Till F., Tyagi, Sandeep, Tasneen, Rokeya, Kim, Jeongjun, Nuermberger, Eric L.
Materialtyp: Artigo
Språk:Inglês
Publicerad: American Society for Microbiology 2020
Ämnen:
Clinical Therapeutics
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC7269501/
https://ncbi.nlm.nih.gov/pubmed/32205344
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00259-20
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk